{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:54:32Z","timestamp":1771566872047,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jval.2019.08.007","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T17:55:06Z","timestamp":1570816506000},"page":"1402-1409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model"],"prefix":"10.1016","volume":"22","author":[{"given":"Hui","family":"Shao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Stoecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongzhe","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.jval.2019.08.007_bib1","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.2337\/dc11-s209","article-title":"Heart in diabetes: a microvascular disease","volume":"34","author":"Laakso","year":"2011","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jval.2019.08.007_bib2","first-page":"105","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b7 9 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet"},{"issue":"10120","key":"10.1016\/j.jval.2019.08.007_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jval.2019.08.007_bib4","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.2337\/dc13-2484","article-title":"The lifetime cost of diabetes and its implications for diabetes prevention","volume":"37","author":"Zhuo","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.jval.2019.08.007_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.amepre.2013.04.017","article-title":"Lifetime direct medical costs of treating type 2 diabetes and diabetic complications","volume":"45","author":"Zhuo","year":"2013","journal-title":"Am J Prev Med"},{"issue":"11","key":"10.1016\/j.jval.2019.08.007_bib6","first-page":"974","article-title":"Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with type 2 diabetes mellitus inadequately controlled by oral therapies","volume":"18","author":"Deng","year":"2015","journal-title":"J\u00a0Med Econ"},{"issue":"2","key":"10.1016\/j.jval.2019.08.007_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/03007995.2016.1257978","article-title":"Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus","volume":"33","author":"Shao","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"10.1016\/j.jval.2019.08.007_bib8","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","article-title":"UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82","volume":"56","author":"Hayes","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jval.2019.08.007_bib9","author":"Hoerger"},{"issue":"8","key":"10.1016\/j.jval.2019.08.007_bib10","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dc08-0521","article-title":"Validation of prediction of diabetes by the Archimedes model and comparison with other predicting models","volume":"31","author":"Stern","year":"2008","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.jval.2019.08.007_bib11","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40273-018-0662-1","article-title":"Novel risk engine for diabetes progression and mortality in USA: building, relating, assessing, and validating outcomes (BRAVO)","volume":"36","author":"Shao","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2019.08.007_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"10.1016\/j.jval.2019.08.007_bib13","article-title":"Cardiovascular disease and diabetes in patients with African or Asian background","volume":"137","author":"Aamb\u00f8","year":"2017","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"2","key":"10.1016\/j.jval.2019.08.007_bib14","doi-asserted-by":"crossref","first-page":"e1000236","DOI":"10.1371\/journal.pmed.1000236","article-title":"Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis","volume":"7","author":"Clarke","year":"2010","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.jval.2019.08.007_bib15","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2337\/dc11-0755","article-title":"Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial","volume":"34","author":"Woodward","year":"2011","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jval.2019.08.007_bib16","doi-asserted-by":"crossref","first-page":"e001577","DOI":"10.1161\/JAHA.114.001577","article-title":"Effect of intensive versus standard blood glucose control in patients with Type 2 diabetes mellitus in different regions of the world: systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"Sardar","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.jval.2019.08.007_bib17","doi-asserted-by":"crossref","first-page":"e 1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PRISMA Group","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"suppl 2","key":"10.1016\/j.jval.2019.08.007_bib18","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1185\/030079904X1980","article-title":"The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making","volume":"20","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.jval.2019.08.007_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J\u00a0Royal Statistical Society. Series B (Methodological)"},{"issue":"4","key":"10.1016\/j.jval.2019.08.007_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jval.2019.08.007_bib21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.jval.2019.08.007_bib22","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.jval.2019.08.007_bib23","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9786","key":"10.1016\/j.jval.2019.08.007_bib24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(11)60698-3","article-title":"Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial","volume":"378","author":"Griffin","year":"2011","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jval.2019.08.007_bib25","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9493","key":"10.1016\/j.jval.2019.08.007_bib26","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jval.2019.08.007_bib27","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9435","key":"10.1016\/j.jval.2019.08.007_bib28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.jval.2019.08.007_bib29","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9681","key":"10.1016\/j.jval.2019.08.007_bib30","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jval.2019.08.007_bib31","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"issue":"7438","key":"10.1016\/j.jval.2019.08.007_bib32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bmj.37970.629537.0D","article-title":"Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)","volume":"328","author":"Marre","year":"2004","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jval.2019.08.007_bib33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9500","key":"10.1016\/j.jval.2019.08.007_bib34","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jval.2019.08.007_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jval.2019.08.007_bib36","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jval.2019.08.007_bib37","first-page":"2545","article-title":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et\u00a0al. Effects of intensive glucose lowering in type 2 diabetes","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jval.2019.08.007_bib38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/01.CIR.91.3.873","article-title":"Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an international registry","volume":"91","author":"Hochman","year":"1995","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jval.2019.08.007_bib39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1474-4422(09)70025-0","article-title":"Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review","volume":"8","author":"Feigin","year":"2009","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jval.2019.08.007_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(03)00266-7","article-title":"Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century","volume":"2","author":"Feigin","year":"2003","journal-title":"Lancet Neurol"},{"issue":"19","key":"10.1016\/j.jval.2019.08.007_bib41","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur. Heart J"},{"issue":"9","key":"10.1016\/j.jval.2019.08.007_bib42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301519323514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301519323514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:16:49Z","timestamp":1761095809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301519323514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1098301519323514"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2019.08.007","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2019.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}